跳转至内容
Merck

1341001

USP

吲哚美辛

United States Pharmacopeia (USP) Reference Standard

别名:

1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-3-吲哚乙酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H16ClNO4
CAS号:
分子量:
357.79
Beilstein:
497341
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

indomethacin

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

COc1ccc2n(c(C)c(CC(O)=O)c2c1)C(=O)c3ccc(Cl)cc3

InChI

1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)

InChI 密鑰

CGIGDMFJXJATDK-UHFFFAOYSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Indomethacin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Indomethacin Capsules
  • Indomethacin Extended-Release Capsules
  • Indomethacin for Injection
  • Indomethacin Oral Suspension
  • Indomethacin Sodium
  • Indomethacin Suppositories

生化/生理作用

环加氧酶 (COX) 抑制剂,对 COX-1 的选择性相对较高。

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Skull and crossbones

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 1 Oral

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Taco J Blokhuis et al.
Clinical orthopaedics and related research, 467(2), 526-530 (2008-09-30)
Heterotopic ossification is a well-known complication after fixation of an acetabular fracture. Indomethacin and radiation therapy are used as prophylaxis to prevent heterotopic ossification. It is unclear, however, whether either is superior, although this may relate to lack of power
Ramesh Chennupati et al.
PloS one, 9(7), e102264-e102264 (2014-07-18)
Argininosuccinate synthetase (ASS) is essential for recycling L-citrulline, the by-product of NO synthase (NOS), to the NOS substrate L-arginine. Here, we assessed whether disturbed arginine resynthesis modulates endothelium-dependent vasodilatation in normal and diabetic male mice. Endothelium-selective Ass-deficient mice (Assfl/fl/Tie2Cretg/- = Ass-KOTie2) were
L J Jones et al.
Archives of disease in childhood. Fetal and neonatal edition, 96(1), F45-F52 (2010-09-30)
To evaluate the effects of indomethacin or ibuprofen compared with placebo on closure, morbidity and mortality in preterm infants <37 weeks' gestation with echocardiographically and/or clinically important patent ductus arteriosus (PDA) at >24 h of life. MEDLINE, EMBASE, Cochrane Central
Brian J Krieg et al.
Journal of pharmaceutical sciences, 103(11), 3473-3490 (2014-09-13)
Development of an oral in vivo predictive dissolution medium for acid drugs with a pKa in the physiological range (e.g., Biopharmaceutics Classification System Class IIa) requires transport analysis of the complex in vivo CO2 /bicarbonate buffering system. In this report
Roland Neumann et al.
Neonatology, 102(1), 9-15 (2012-03-15)
Pharmacological closure of patent ductus arteriosus (PDA) is commonly achieved by intravenous (IV) administration of ibuprofen or indomethacin. Occasionally, oral ibuprofen is used for PDA treatment although its efficacy and safety are unclear. To systematically review randomized and quasi-randomized trials

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门